Ephrina1 Is released in three forms from cancer cells by matrix Metalloproteases

Molecular and Cellular Biology

Volumn 32, Issue 16, 2012, Pages 3253-3264

  Beauchamp, Amanda ^a   Lively, Mark O ^a   Mintz, Akiva ^a   Gibo, Denise ^a   Wykosky, Jill ^b   Debinski, Waldemar ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; COLLAGENASE 3; EPHRIN A1; EPHRIN RECEPTOR A2; GELATINASE A; GELATINASE B; GLYCOSYLPHOSPHATIDYLINOSITOL; HISTIDINE; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; RECOMBINANT EPHRIN A1; RECOMBINANT PROTEIN; SERINE; UNCLASSIFIED DRUG; VALINE;

AMINO ACID SEQUENCE; APOPTOSIS; ARTICLE; CANCER CELL; CARBOXY TERMINAL SEQUENCE; CELL MEMBRANE; CELL PROLIFERATION; CONTROLLED STUDY; GENE DELETION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SECRETION; RECEPTOR DOWN REGULATION; WESTERN BLOTTING;

AMINO ACID SEQUENCE; CELL LINE, TUMOR; CELL MOVEMENT; CULTURE MEDIA, CONDITIONED; EPHRIN-A1; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIGANDS; MASS SPECTROMETRY; MATRIX METALLOPROTEINASES; MOLECULAR SEQUENCE DATA; MUTATION; NEOPLASMS; PEPTIDES; PHOSPHOINOSITIDE PHOSPHOLIPASE C; PROTEOLYSIS; RECOMBINANT PROTEINS; TRANSFECTION;

EID: 84865109690     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.06791-11     Document Type: Article

References (71)

1. Adibhatla RM, Hatcher JF. 2008. Tissue plasminogen activator (tPA) and matrix metalloproteinases in the pathogenesis of stroke: therapeutic strategies. CNS Neurol. Disord. Drug Targets 7:243-253.
2. Alford S, et al. 2010. Soluble ephrin a1 is necessary for the growth of HeLa and SK-BR3 cells. Cancer Cell Int. 10:41.
3. Alford SC, Bazowski J, Lorimer H, Elowe S, Howard PL. 2007. Tissue transglutaminase clusters soluble A-type ephrins into functionally active high molecular weight oligomers. Exp. Cell Res. 313:4170-4179.
4. Anand M, Van Meter T, Fillmore H. 2011. Epidermal growth factor induces matrix metalloproteinase-1 (MMP-1) expression and invasion in glioma cell lines via the MAPK pathway. J. Neurooncol. 104:679-687.
5. Bartley TD, et al. 1994. B61 is a ligand for the ECK receptor proteintyrosine kinase. Nature 368:558-560.
6. Beauchamp A, Debinski W. 2012. Ephs and ephrins in cancer: ephrin-A1 signalling. Semin. Cell Dev. Biol. 23:109-115.
7. Beckmann MP, et al. 1994. Molecular characterization of a family of ligands for eph-related tyrosine kinase receptors. EMBO J. 13:3757-3762.
8. Bong Y-S, et al. 2007. ephrinB1 signals from the cell surface to the nucleus by recruitment of STAT3. Proc. Natl. Acad. Sci. U. S. A. 104:17305-17310.
9. Brinckerhoff CE, Rutter JL, Benbow U. 2000. Interstitial collagenases as markers of tumor progression. Clin. Cancer Res. 6:4823-4830.
10. Choe G, et al. 2002. Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype. Clin. Cancer Res. 8:2894-2901.
11. Cui X-D, et al. 2010. EFNA1 ligand and its receptor EphA2: potential biomarkers for hepatocellular carcinoma. Int. J. Cancer 126:940-949.
12. Davis S, et al. 1994. Ligands for EPH-related receptor tyrosine kinases that require membrane attachment or clustering for activity. Science 266: 816-819.
13. Davy A, et al. 1999. Compartmentalized signaling by GPI-anchored ephrin-A5 requires the Fyn tyrosine kinase to regulate cellular adhesion. Genes Dev. 13:3125-3135.
14. Debinski W. 2008. Drug cocktails for effective treatment of glioblastoma multiforme. Expert Rev. Neurother. 8:515-517.
15. Dunaway CM, et al. 2011. Cooperative signaling between Slit2 and ephrin-A1 regulates a balance between angiogenesis and angiostasis. Mol. Cell. Biol. 31:404 - 416.
16. Egea J, et al. 2005. Regulation of EphA4 kinase activity is required for a subset of axon guidance decisions suggesting a key role for receptor clustering in Eph function. Neuron 47:515-528.
17. Finne EF, Aasheim MEHC. 2004. A new ephrin-A1 isoform (ephrin-A1b) with altered receptor binding properties abrogates the cleavage of ephrin-A1a. Biochem. J. 379(Pt 1):39-46.
18. Gale NW, Yancopoulos GD. 1997. Ephrins and their receptors: a repulsive topic? Cell Tissue Res. 290:227-241.
19. Gale NW. 1996. Eph receptors and ligands comprise two major specificity subclasses and are reciprocally compartmentalized during embryogenesis. Neuron 17:9-19.
20. Gialeli C, Theocharis AD, Karamanos NK. 2011. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J. 278:16-27.
21. Hagemann C, Anacker J, Haas S, Riesner D, Schömig B, Ernestus R-I, Vince GH. 2010. Comparative expression pattern of Matrix-Metalloproteinases in human glioblastoma cell-lines and primary cultures. BMC Res. Notes 3:293.
22. Hattori M, Osterfield M, Flanagan JG. 2000. Regulated cleavage of a contact-mediated axon repellent. Science 289:1360-1365.
23. Himanen J-P, et al. 2004. Repelling class discrimination: ephrin-A5 binds to and activates EphB2 receptor signaling. Nat. Neurosci. 7:501-509.
24. Himanen J-P, et al. 2001. Crystal structure of an Eph receptor-ephrin complex. Nature 414:933-938.
25. Himanen J-P, Saha N, Nikolov DB. 2007. Cell-cell signaling via Eph receptors and ephrins. Curr. Opin. Cell Biol. 19:534-542.
26. Himanen JP, et al. 2010. Architecture of Eph receptor clusters. Proc. Natl. Acad. Sci. U. S. A. 107:10860-10865.
27. Himanen JP, et al. 2009. Ligand recognition by A-class Eph receptors: crystal structures of the EphA2 ligand-binding domain and the EphA2/ephrin-A1 complex. EMBO Rep. 10:722-728.
28. Holen HL, et al. 2008. Signaling through ephrin-A ligand leads to activation of Src-family kinases, Akt phosphorylation, and inhibition of antigen receptor-induced apoptosis. J. Leukoc. Biol. 84:1183-1191.
29. Holzman LB, Marks RM, Dixit VM. 1990. A novel immediate-early response gene of endothelium is induced by cytokines and encodes a secreted protein. Mol. Cell. Biol. 10:5830-5838.
30. Ikezawa H. 2002. Glycosylphosphatidylinositol (GPI)-anchored proteins. Biol. Pharm. Bull. 25:409-417.
31. Irie N, et al. 2009. Bidirectional signaling through ephrinA2-EphA2 enhances osteoclastogenesis and suppresses osteoblastogenesis. J. Biol. Chem. 284:14637-14644.
32. Janes PW, et al. 2005. Adam meets Eph: an ADAM substrate recognition module acts as a molecular switch for ephrin cleavage in trans. Cell 123: 291-304.
33. Janes PW, et al. 2009. Cytoplasmic relaxation of active Eph controls ephrin shedding by ADAM10. PLoS Biol. 7:e1000215. doi:10.1371/journal.pbio.1000215.
34. Klein T, Bischoff R. 2011. Physiology and pathophysiology of matrix metalloproteases. Amino Acids 41:271-290.
35. Krane SM. 2001. Petulant cellular acts: destroying the ECM rather than creating it. J. Clin. Invest. 107:31-32.
36. Kullander K, Klein R. 2002. Mechanisms and functions of Eph and ephrin signalling. Nat. Rev. Mol. Cell Biol. 3:475-486.
37. Lampert K, Machein U, Machein MR, Conca W, Peter HH, Volk B. 1998. Expression of matrix metalloproteinases and their tissue inhibitors in human brain tumors. Am. J. Pathol. 153:429-437.
38. Lee H-S, et al. 2006. Dishevelled mediates ephrinB1 signalling in the eye field through the planar cell polarity pathway. Nat. Cell Biol. 8:55-63.
39. Leeman MF, Curran S, Murray GI. 2002. The structure, regulation, and function of human matrix metalloproteinase-13. Crit. Rev. Biochem. Mol. Biol. 37:149-166.
40. Levicar N, Nutall RK, Lah TT. 2003. Proteases in brain tumour progression. Acta Neurochir. 145:825-838.
41. Lim Y-S, et al. 2008. p75NTR mediates ephrin-A reverse signaling required for axon repulsion and mapping. Neuron 59:746-758.
42. Lin K-T, Sloniowski S, Ethell DW, Ethell IM. 2008. Ephrin-B2-induced cleavage of EphB2 receptor is mediated by matrix metalloproteinases to trigger cell repulsion. J. Biol. Chem. 283:28969-28979.
43. Lu D-Y, Leung Y-M, Cheung C-W, Chen Y-R, Wong K-L. 2010. Glial cell line-derived neurotrophic factor induces cell migration and matrix metalloproteinase-13 expression in glioma cells. Biochem. Pharmacol. 80: 1201-1209.
44. Macrae M, et al. 2005. A conditional feedback loop regulates Ras activity through EphA2. Cancer Cell 8:111-118.
45. Marler K, Poopalasundaram S, Broom E, Wentzel C, Drescher U. 2010. Pro-neurotrophins secreted from retinal ganglion cell axons are necessary for ephrinA-p75NTR-mediated axon guidance. Neural Dev. 5:30.
46. Marler KJ, et al. 2008. A TrkB/EphrinA interaction controls retinal axon branching and synaptogenesis. J. Neurosci. 28:12700-12712.
47. Miao H, Burnett E, Kinch M, Simon E, Wang B. 2000. Activation of EphA2 kinase suppresses integrin function and causes focal-adhesionkinase dephosphorylation. Nat. Cell Biol. 2:62-69.
48. Mott JD, Werb Z. 2004. Regulation of matrix biology by matrix metalloproteinases. Curr. Opin. Cell Biol. 16:558-564.
49. Murai KK, Pasquale EB. 2003. 'Eph'ective signaling: forward, reverse and crosstalk. J. Cell Sci. 116:2823-2832.
50. Pasquale EB. 2008. Eph-Ephrin bidirectional signaling in physiology and disease. Cell 133:38-52.
51. Pezzato E, et al. 2003. Proteinase-3 directly activates MMP-2 and degrades gelatin and Matrigel; differential inhibition by (minus)epigallocatechin-3-gallate. J. Leukoc. Biol. 74:88-94.
52. Pullen NA, Anand M, Cooper PS, Fillmore HL. 2012. Matrix metalloproteinase-1 expression enhances tumorigenicity as well as tumor-related angiogenesis and is inversely associated with TIMP-4 expression in a model of glioblastoma. J. Neurooncol. 106:461-471.
53. Raithatha SA, et al. 2000. Localization of gelatinase-A and gelatinase-B mRNA and protein in human gliomas. Neuro Oncol. 2:145-150.
54. Roy R, Yang J, Moses MA. 2009. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J. Clin. Oncol. 27:5287-5297.
55. Saunders WB, Bayless KJ, Davis GE. 2005. MMP-1 activation by serine proteases and MMP-10 induces human capillary tubular network collapse and regression in 3D collagen matrices. J. Cell Sci. 118:2325-2340.
56. Shao H, Pandey A, O'Shea KS, Seldin M, Dixit VM. 1995. Characterization of B61, the ligand for the Eck receptor protein-tyrosine kinase. J. Biol. Chem. 270:5636-5641.
57. Singla N, et al. 2010. Crystal structure of the ligand-binding domain of the promiscuous EphA4 receptor reveals two distinct conformations. Biochem. Biophys. Res. Commun. 399:555-559.
58. Stojic J, et al. 2008. Expression of matrix metalloproteinases MMP-1, MMP-11 and MMP-19 is correlated with the WHO-grading of human malignant gliomas. Neurosci. Res. 60:40-49.
59. Stupp R, et al. 2005. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352:987-996.
60. Tanaka M, Sasaki K, Kamata R, Sakai R. 2007. The C-terminus of ephrin-B1 regulates metalloproteinase secretion and invasion of cancer cells. J. Cell Sci. 120:2179-2189.
61. Vearing CJ, Lackmann M. 2005. "Eph receptor signalling; dimerisation just isn't enough." Growth Factors 23:67-76.
62. Walker-Daniels J, Riese DJ, Kinch MS. 2002. c-Cbl-dependent EphA2 protein degradation is induced by ligand binding. Mol. Cancer Res. 1:79 - 87.
63. Wang LF, et al. 2008. Increased expression of EphA2 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients. Oncol. Rep. 19:151-156.
64. Wei S, et al. 2010. ADAM13 induces cranial neural crest by cleaving class B ephrins and regulating Wnt signaling. Dev. Cell 19:345-352.
65. Winslow JW, et al. 1995. Cloning of AL-1, a ligand for an Eph-related tyrosine kinase receptor involved in axon bundle formation. Neuron 14: 973-981.
66. Wykosky J, Debinski W. 2008. The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting. Mol. Cancer Res. 6:1795-1806.
67. Wykosky J, Gibo DM, Debinski W. 2007. A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor expressing tumor cells. Mol. Cancer Ther. 6:3208-3218.
68. Wykosky J, Gibo DM, Stanton C, Debinski W. 2005. EphA2 as a novel molecular marker and target in glioblastoma multiforme. Mol. Cancer Res. 3:541-551.
69. Wykosky J, Gibo DM, Stanton C, Debinski W. 2008. Interleukin-13 receptor alpha 2, EphA2, and Fos-related antigen 1 as molecular denominators of high-grade astrocytomas and specific targets for combinatorial therapy. Clin. Cancer Res. 14:199-208.
70. Wykosky J, et al. 2008. Soluble monomeric ephrinA1 is released from tumor cells and is a functional ligand for the EphA2 receptor. Oncogene 27:7260-7273.
71. Zhang Y, et al. 2011. Upregulation of matrix metalloproteinase-1 and proteinase-activated receptor-1 promotes the progression of human gliomas. Pathol. Res. Pract. 207:24-29.